More rebates in Italy threaten profitability of pure biotech firms like Amgen and Celgene
This article was originally published in Scrip
Executive Summary
Pure biotech companies operating in Italy will have trouble staying profitable if next year they have to stump up some €800 million in the form of rebates, Riccardo Palmisano, senior vice- president of Italy's biotech association, Assobiotec, told Scrip. The biotech companies operating in Italy, which include Amgen, Genzyme and Celgene, are particularly exposed to potential clawback because their products are almost exclusively sold to hospitals, the drugs budget for which is being strictly capped.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.